Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | THRA | P10827 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937173 | 0.98 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL11751290 | 0.98 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL2590590 | 0.95 | — | — | |
| SCHEMBL2265196 | 0.90 | LMNA (0.41) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL2966870 | 0.90 | — | — | |
| SCHEMBL1672623 | 0.80 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL1669840 | 0.78 | LMNA (0.59) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL8396781 | 0.78 | LMNA (0.53) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL4463734 | 0.78 | LMNA (0.59) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL29063243 | 0.77 | SCN9A (0.36) | LMNASLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118930552-A | Isobenzofuran-1 (3H) -one compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-11-12 | — | — | CN | disclosed |
| CN-108779096-B | Fluorine-substituted cyclopropylamine compounds, and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-07-01 | — | — | CN | disclosed |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-17 | — | — | US | disclosed |
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-04 | — | — | US | disclosed |
| EP-3431471-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USERS THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-01-23 | — | — | EP | disclosed |
| CN-108779096-A | A kind of fluorine-substituted cyclopropylamine class compound and preparation method thereof, pharmaceutical composition and purposes | 中国科学院上海药物研究所 | 2018-11-09 | — | — | CN | disclosed |
| CN-107200706-A | Cyclopropylamine class compound of one class fluorine substitution and preparation method thereof, pharmaceutical composition and purposes | 中国科学院上海药物研究所 | 2017-09-26 | — | — | CN | disclosed |
| US-7728148-B2 | Acyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1472230-B1 | ANSAMYCINS HAVING IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES | CONFORMA THERAPEUTICS CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7465718-B2 | Ansamycins having improved pharmacological and biological properties | CONFORMA THERAPEUTICS CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| WO-2007146695-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20050267122-A1 | Ansamycins having improved pharmacological and biological properties | Zhang, Lin | 2005-12-01 | — | — | US | disclosed |
| EP-1472230-A4 | ANSAMYCINS HAVING IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES | CONFORMA THERAPEUTIC CORP (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1472230-A2 | ANSAMYCINS HAVING IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES | Conforma Therapeutic Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066005-A2 | ANSAMYCINS HAVING IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES | CONFORMA THERAPEUTICS CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
| WO-1997049668-A1 | INHIBITIORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-31 | — | — | WO | disclosed |
| US-4591583-A | TREATING VIRAL INFECTIONS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1986-05-27 | — | — | US | disclosed |
| US-4386081-A | VIRICIDE | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1983-05-31 | — | — | US | disclosed |
| EP-0003007-B1 | ALIPHATIC DERIVATIVES OF PHOSPHONOFORMIC ACID, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COMBATING VIRUS INFECTIONS | Astra Läkemedel Aktiebolag (SE) | 1982-04-07 | — | — | EP | disclosed |
| EP-0003007-A2 | Aliphatic derivatives of phosphonoformic acid, pharmaceutical compositions and methods for combating virus infections | Astra Läkemedel Aktiebolag (SE) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267122-A1 | Ansamycins having improved pharmacological and biological properties | NARS1, AAAS, ASNS | LMNA 474/4885SLC1A3 4113/4885SLC1A2 4064/4885 |
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SETDB1, KDM1B, SETD7 | LMNA 3149/4885SLC1A3 1177/4885SLC1A2 1289/4885 |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SETDB1, KDM1B, SETD7 | LMNA 3149/4885SLC1A3 1177/4885SLC1A2 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.